Samsung Electronics Co., Ltd.

Ildong Pharm Co., Ltd.

Orum Therapeutics Inc.

Sungkyunkwan University

Ajou University Industry-academic Cooperation Foundation

Il Dong Pharmaceutical Co., Ltd.

Invitroplant Co., Ltd.

Ministry of Agriculture Food and Rural Affairs Animal and Plant Quarantine Agency

Hp Printing Korea Co., Ltd.

Ministry for Food, Agriculture, Forestry and Fisheries, National Veterinary Research and Quarantive Service

Yong-Sung Kim

Tae-Young Chung

Jae-Hoon Kang

Sung-Hoon Kim

Jin-Woo Lee

Hyuk Sang Kwon

Seung-Min Shin

Seong Beom Kim

Dong-Ki Choi

Hyei Yoon Jung

Seok Woo Yang

Young-Min Lee

Seung-Hyun Lee

Eun Jin Choi

Woo-Ram Lee

Chan-Wook Baik

Young-Rim Kim

Yong-Seok Jung

Joo-Ho Lee

Myung-Hee Kwon

Hyuk-Sang Kwon

Ji-Young Jang

Jae Young Song

Jong-Nam Sohn

Yi-Jung Jung

Ki-Yoon Kim

Yu-Chul Chung

Eul-Yong Park

Hye-Kyung Shim

Gun-Sup Lee

Jeong-Sun Kim

Tai-Hyun Kim

Suk-Chan Lee

Jong-Hee Ko

Hyei-Yoon Jung

Seok-Woo Yang

Chang-Seung Lee

Chang-Youl Moon

Jun-Seong Kim

Jong-Pil Jun

Ho-Young Ahn

Yu-Chul Jung

The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.

Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused

Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.

Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases

The present disclosure relates to a method for inhibiting intracellular activated (GTP-bound) RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol, and to the use thereof. The disclosure further relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to penetrate the cytosol and bind to activated RAS in the cytosol, and to an antibody comprising the same. The disclosure correspondingly provides a method for inhibiting the growth of cancer or tumor cells using the antibody, and a method for treating cancer or tumor.

Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof

A method is described of localizing an intact immunoglobulin-format antibody in cytosol by permeating the cell membrane, thereby avoiding the necessity to use a special external protein delivery system. The method achieves high effects on the treatment and diagnosis of tumor and disease-related factors that show structurally complex interactions through a wide and flat surface between protein and protein.

Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same

Provided is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Also provided is an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.

Antiviral agent against animal viruses

A metal oxide semiconductor (MOS) includes an isolation layer disposed in a semiconductor substrate to define an active region. A source region and a drain region are disposed on both sides of the active region such that a first direction is defined from the source region to the drain region. A channel recess is disposed in the active region between the source and drain regions. The channel recess has a convex surface when viewed from a cross-sectional view taken along a second direction orthogonal to the first direction. A gate electrode fills the channel recess and crosses the active region in the second direction. A gate insulating layer is interposed between the gate electrode and the active region.

Metal oxide semiconductor (MOS) transistors having a recessed gate electrode

According to some embodiments of the invention, transistors have channel regions between channel-portion holes. Methods of forming the same include at least two channel-portion holes disposed in a semiconductor substrate. Line patterns are formed in parallel to be spaced apart from each other on a main surface of the semiconductor substrate to fill the channel-portion holes. A channel region is disposed in the semiconductor substrate below the line patterns. At this time, the channel region is formed between the channel-portion holes and also covers lower portions of the channel-portion holes. Driving current capability and refresh characteristics of DRAMs utilizing the inventive transistors are improved.

Transistors having a channel region between channel-portion holes and methods of forming the same

Metal oxide semiconductor (MOS) transistor having a recessed gate electrode and methods of fabricating the same

Growing community of inventors

Gyeonggi-do, South Korea

Yong-Sung Kim